| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Grossman, R Ross, J A Wass, G M Besse. Depot-bromocriptine treatment for prolactinomas and acromegaly. Clinical endocrinology. vol 24. issue 2. 1986-07-24. PMID:3708874. |
of the four patients with acromegaly, raised prolactin levels were successfully lowered to normal for 4 weeks after injection; serum gh was also partially lowered, but returned to baseline levels at 2-4 weeks. |
1986-07-24 |
2023-08-11 |
Not clear |
| T Shibasaki, M Hotta, A Masuda, T Imaki, N Obara, N Hizuka, K Takano, I Wakabayashi, H Demura, N Lin. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly. The Journal of clinical endocrinology and metabolism. vol 63. issue 1. 1986-07-18. PMID:2872226. |
studies on the response of growth hormone (gh) secretion to gh-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly. |
1986-07-18 |
2023-08-11 |
human |
| M Losa, P G Chiodini, A Liuzzi, A König, O A Müller, J Schopohl, K von Werde. Growth hormone-releasing hormone infusion in patients with active acromegaly. The Journal of clinical endocrinology and metabolism. vol 63. issue 1. 1986-07-18. PMID:3086362. |
to determine gh-releasing hormone (ghrh)-stimulated gh secretion in patients with active acromegaly, nine patients received a 50-microgram ghrh-(1-44) bolus dose followed by a 2-h infusion with 100 micrograms ghrh/h, after which a second 50-microgram ghrh bolus dose was given. |
1986-07-18 |
2023-08-11 |
human |
| M Losa, P G Chiodini, A Liuzzi, A König, O A Müller, J Schopohl, K von Werde. Growth hormone-releasing hormone infusion in patients with active acromegaly. The Journal of clinical endocrinology and metabolism. vol 63. issue 1. 1986-07-18. PMID:3086362. |
these findings suggest that patients with active acromegaly not only have elevated basal gh levels, but also have a greater ready releasable gh pool and/or accelerated gh turnover compared to those of normal subjects, which cannot be exhausted by a 2-h ghrh infusion. |
1986-07-18 |
2023-08-11 |
human |
| P M Bell, A B Atkinson, D R Hadden, L Kennedy, H Leslie, J D Merrett, B Sherida. Bromocriptine reduces growth hormone in acromegaly. Archives of internal medicine. vol 146. issue 6. 1986-07-03. PMID:3718102. |
we assessed serum growth hormone (gh) levels in ten patients with acromegaly during a 24-hour profile and a 75-g oral glucose tolerance test (gtt). |
1986-07-03 |
2023-08-11 |
Not clear |
| J M García López, A De la Fuente, M A Tomé, J A Mato Mato, G J Gaudiero, A Odriozola, J Cabezas-Cerrat. Acromegaly and insulin resistance: a case study. Acta endocrinologica. vol 111. issue 4. 1986-06-12. PMID:3010619. |
we have studied the relationship between impaired glucose metabolism and its variations with different plasma levels of endogenous gh in one patient with acromegaly. |
1986-06-12 |
2023-08-11 |
Not clear |
| H Tsuchiya, T Onishi, S Takamoto, S Morimoto, K Fukuo, S Imanaka, H Yamamoto, S Yukawa, E Koh, T Sonod. An acromegalic patient with recurrent urolithiasis. Endocrinologia japonica. vol 32. issue 6. 1986-05-30. PMID:3841720. |
these findings suggest that gh may promote the activation of vitamin d in the kidney in acromegaly, resulting in an acceleration of calcium absorption in the intestine through the action of activated vitamin d and the induction of increased urinary calcium excretion by the urinary excretion of excessive blood calcium. |
1986-05-30 |
2023-08-11 |
Not clear |
| A Coppola, C Spera, V Buono, C Esposito, A Nast. [Acromegaly. Physiopathological aspects and description of a clinical case]. Minerva medica. vol 77. issue 11. 1986-05-27. PMID:3085021. |
recent physiopathological studies suggest that hypersecretion of gh in acromegaly is not necessarily the result of a primary alteration to the gh-secreting pituitary cells. |
1986-05-27 |
2023-08-11 |
Not clear |
| S Skare, V Kriz, K F Hansse. Somatostatin, insulin and glucagon after arginine stimulation in active and treated acromegaly. Acta endocrinologica. vol 111. issue 2. 1986-04-10. PMID:2869632. |
plasma srif is similar in active acromegaly and normal controls, and in acromegaly before and following treatment, despite differences in serum growth hormone (gh), serum insulin and plasma glucagon. |
1986-04-10 |
2023-08-11 |
Not clear |
| D B Karpf, G D Braunstei. Current concepts in acromegaly: etiology, diagnosis, and treatment. Comprehensive therapy. vol 12. issue 1. 1986-03-31. PMID:3948488. |
acromegaly is an insidious disorder of somatic growth and metabolic derangements that results from the chronic hypersecretion of growth hormone (gh) in the adult. |
1986-03-31 |
2023-08-11 |
Not clear |
| R Cozzi, D Dallabonzana, G Oppizzi, G Verde, A Liuzzi, P G Chiodin. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly. The Journal of clinical endocrinology and metabolism. vol 62. issue 3. 1986-03-13. PMID:3080469. |
bromocriptine does not alter growth hormone (gh) responsiveness to gh-releasing hormone in acromegaly. |
1986-03-13 |
2023-08-11 |
Not clear |
| K G Thorngren, B Hallengre. Bioassayable growth hormone activity in blood from healthy individuals and acromegalic patients. Acta endocrinologica. vol 111. issue 1. 1986-03-04. PMID:3946103. |
biological growth activity (bioassayable gh) was determined in blood from healthy individuals and from patients with acromegaly using the rate of longitudinal bone growth in hypophysectomized rats with tetracycline as intravital marker. |
1986-03-04 |
2023-08-11 |
human |
| M Arosio, B Ambrosi, L Guglielmino, G Fagli. Human pancreatic growth hormone-releasing factor (hpGRF-44) in acromegaly before and after adenomectomy. Modifications induced by somatostatin (GHRIH) infusion. Journal of endocrinological investigation. vol 8. issue 5. 1986-02-14. PMID:2867112. |
the influence of human pancreatic growth hormone-releasing factor (hpgrf-44) on gh secretion was investigated in 15 patients with active acromegaly. |
1986-02-14 |
2023-08-11 |
human |
| O Serri, M Somma, R Comtois, E Rasio, H Beauregard, N Jilwan, J Hard. Acromegaly: biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy. The Journal of clinical endocrinology and metabolism. vol 61. issue 6. 1985-12-13. PMID:4055986. |
we conclude that recurrence of acromegaly after successful surgery may occur late after adenoma removal and that it cannot be predicted by normal postoperative gh levels and dynamics. |
1985-12-13 |
2023-08-11 |
Not clear |
| M Ishibashi, T Fukushima, T Yamaj. Cyproheptadine-mediated inhibition of growth hormone and prolactin release from pituitary adenoma cells of acromegaly and gigantism in culture. Acta endocrinologica. vol 109. issue 4. 1985-10-23. PMID:2994332. |
the effect of cyproheptadine on growth hormone (gh) and prolactin (prl) secretion from cultured pituitary adenoma cells of acromegaly and pituitary gigantism was studied. |
1985-10-23 |
2023-08-11 |
human |
| M Giusti, A Lomeo, G Mazzocchi, D Mignone, P Sessarego, M Monachesi, G Giordan. The effects of growth hormone-releasing factor (GRF) and dopamine on growth hormone (GH) secretion in acromegaly. Journal of endocrinological investigation. vol 8. issue 3. 1985-10-15. PMID:3928732. |
the effects of growth hormone-releasing factor (grf) and dopamine on growth hormone (gh) secretion in acromegaly. |
1985-10-15 |
2023-08-11 |
Not clear |
| M Giusti, A Lomeo, G Mazzocchi, D Mignone, P Sessarego, M Monachesi, G Giordan. The effects of growth hormone-releasing factor (GRF) and dopamine on growth hormone (GH) secretion in acromegaly. Journal of endocrinological investigation. vol 8. issue 3. 1985-10-15. PMID:3928732. |
our data underscore that in acromegaly the da tonus inhibits gh secretion after grf by acting directly at the pituitary level. |
1985-10-15 |
2023-08-11 |
Not clear |
| D Dallabonzana, A Liuzzi, G Oppizzi, G Verde, P G Chiodini, R Dorow, R Horowsk. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly. Journal of endocrinological investigation. vol 8. issue 2. 1985-10-07. PMID:4031381. |
effect of the new ergot derivative terguride on plasma prl and gh levels in patients with pathological hyperprolactinemia or acromegaly. |
1985-10-07 |
2023-08-11 |
human |
| D Dallabonzana, A Liuzzi, G Oppizzi, G Verde, P G Chiodini, R Dorow, R Horowsk. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly. Journal of endocrinological investigation. vol 8. issue 2. 1985-10-07. PMID:4031381. |
we have studied the effects on prl and gh levels of 0.2 mg po of terguride in 8 normal subjects, in 15 patients with pathological hyperprolactinemia (php) and in 17 patients with active acromegaly. |
1985-10-07 |
2023-08-11 |
human |
| S Werner, E af Trampe, P Palacios, I Lax, K Hal. Growth hormone producing pituitary adenomas with concomitant hypersecretion of prolactin are particularly sensitive to photon irradiation. International journal of radiation oncology, biology, physics. vol 11. issue 9. 1985-10-04. PMID:4030438. |
the effect of photon irradiation (50 gy with a 3-field technique in fractionated doses) on growth hormone (gh), prolactin (prl), and somatomedin a (sma) was studied in 25 patients with acromegaly after previous unsuccessful surgery. |
1985-10-04 |
2023-08-11 |
Not clear |